Navigation Links
Transcept Pharmaceuticals to Present at Two Upcoming Conferences

--BIO-Europe Spring(R) 2009 in Milan, Italy--

--Cowen and Company 29th Annual Health Care Conference in Boston, MA--

PT. RICHMOND, Calif., March 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that the Company will present at two upcoming conferences:

  • Glenn A. Oclassen, President and Chief Executive Officer, will present at Bio-Europe Spring(R) 2009, to be held at the Milano Convention Centre (MIC) in Milan on Tuesday, March 17, 2009, at 4:30 p.m. CET (10:30 a.m. ET).
  • Thomas P. Soloway, Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 29th Annual Health Care Conference, to be held at the Boston Marriott Copley Place in Boston, MA, on Tuesday, March 17, 2009, at 9:30 a.m. ET.

An audio webcast of Mr. Soloway's presentation will be available live and archived for 30 days at

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) is positioned to be the first commercially available sleep aid specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009, to the Intermezzo(R) NDA.

For further information, please visit the company's website at:

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Intermezzo(R) being the first commercially available sleep aid in its target indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, or unexpected expenses incurred in connection with, obtaining regulatory approval, market acceptance and commercialization of Intermezzo(R).


    Transcept Pharmaceuticals, Inc.
    Michael Gill
    Director of Communications
    (510) 215-3575

    The Ruth Group
    Investors / Media
    Stephanie Carrington / Jason Rando
    (646) 536-7017 / 7025

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... MENLO PARK, Calif. , Oct. 12, ... of R&D and Chief Scientific Officer of ... leading biotechnology company in the emerging field ... BioPharma Dealmakers webcast, sponsored in part by ... medicine. Dr. Lebkowski will discuss the progress ...
(Date:10/12/2015)... 12, 2015 The global infertility treatment ... million by 2020 from USD 1,822.32 million in ... and 2020. By product, the market includes antivibration ... systems, micromanipulator systems, ovum aspiration pumps, sperm analyzer ... market is segmented into in vitro fertilization, artificial ...
(Date:10/12/2015)... -- Elbit Imaging Ltd. ("EI" or the "Company") ... of directors approved a program to repurchase up to NIS ... Notes and Series I Notes, which are traded on the ... Company will have a significant preference to the purchase Series ... time in the open market on the Tel Aviv Stock ...
Breaking Medicine Technology: